专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

JP2019147020A 幹細胞と標的組織の相互接続を促進する生体適合性基材およびそれを埋め込む方法审中-公开
公开(公告)号：JP2019147020A
公开(公告)日：2019-09-05
申请号：JP2019108763
申请日：2019-06-11
申请人： UNIV SOUTHERN CALIFORNIA , CALIFORNIA INST OF TECHN , UNIV CALIFORNIA
发明人： MARK HUMAYUN , ASHISH AHUJA , TAI YU-CHONG , DAVID HINTON , ROBERT GRUBBS , DENNIS CLEGG , LINCOLN VALLANCE JOHNSON , SHERRY T HIKITA
IPC分类号： A61L27/16 , A61K35/30 , A61K35/545 , A61L27/38
摘要：【課題】細胞療法のための、投与される細胞の活性および有益な効果を標的組織で長期間増強する、標的組織に細胞を投与するための特定の装置および方法を提供する。【解決手段】本明細書に記載した、細胞死、損傷または機能喪失を誘発する種々の疾患の治療を必要とする標的組織への細胞送達のための基材により、上記課題を解決する。この基材は、幹細胞を含めた播種された細胞を提供するように構成され、細胞と標的組織の相互接続およびその間の生体シグナルの伝達を可能にする構造支持体を有する。【選択図】図7

2. 发明专利

JP2007330266A Adipose-derived stem cells and lattices 审中-公开
标题翻译： ADIPOSE-DERIVED STEM CELLS AND LATTICES
公开(公告)号：JP2007330266A
公开(公告)日：2007-12-27
申请号：JP2007200588
申请日：2007-08-01
申请人： Univ California , ザリージェンツオブザユニバーシティオブカリフォルニア
发明人： HEDRICK MARC H , KATZ ADAM J , LLULL RAMON , FUTRELL J WILLIAM , BENHAIM PROSPER , LORENZ HERMANN PETER , ZHU MIN
IPC分类号： C12N15/09 , A01K67/027 , A61K35/12 , A61K48/00 , A61L27/00 , C12M3/08 , C12N5/00 , C12N5/074 , C12N5/077 , C12N5/0775 , C12N5/0789 , C12N5/10
CPC分类号： C12N5/0667 , A61K35/12 , A61K48/00 , C12N5/0068 , C12N2500/25 , C12N2500/38 , C12N2500/42 , C12N2501/01 , C12N2501/15 , C12N2501/33 , C12N2501/39 , C12N2510/00 , C12N2533/90
摘要： PROBLEM TO BE SOLVED: To provide adipose-derived stem cells (ADSCs), adipose-derived stem cell-enriched fractions (ADSC-EF), adipose-derived lattices alone not containing the ADSCs and adipose-derived lattices combined with the ADSCs. SOLUTION: The ADSCs can be employed, alone or within biologically-compatible compositions, to generate differentiated tissues and structures, both in vivo and in vitro. Additionally, the ADSCs can be expanded and cultured to produce molecules such as hormones, In another aspect, the adipose-derived lattice can be used as a substrate to facilitate the growth and differentiation of cells, whether in vivo or in vitro, into anlagen or even mature tissues or structures. COPYRIGHT: (C)2008,JPO&INPIT
摘要翻译：要解决的问题：为了提供脂肪来源的干细胞（ADSC），脂肪来源的干细胞富集的部分（ADSC-EF），单独不含ADSC和脂肪衍生的结合的脂肪衍生的格子与脂肪干细胞。解决方案：ADSC可以单独使用或在生物相容的组合物内使用，以在体内和体外产生分化的组织和结构。另外，ADSC可以被扩增和培养以产生诸如激素的分子。另一方面，脂肪衍生的晶格可以用作底物，以促进细胞的生长和分化，无论是在体内还是在体外，成为原生质体或细胞甚至成熟的组织或结构。版权所有（C）2008，JPO＆INPIT

3. 发明专利

JP2007270148A Method of high-throughput screening for internalizing antibody 有权
标题翻译：用于内部抗体的高通量筛选方法
公开(公告)号：JP2007270148A
公开(公告)日：2007-10-18
申请号：JP2007078868
申请日：2007-03-26
申请人： Univ California , ザリージェンツオブザユニバーシティオブカリフォルニア
发明人： MARKS JAMES D , NIELSEN ULRIK B , KIRPOTIN DMITRI B
IPC分类号： C08L101/14 , G01N33/50 , A61K9/127 , A61K31/519 , A61K45/00 , A61K47/34 , A61P35/00 , C12N15/09 , C12Q1/02 , C12Q1/04 , C40B30/04 , G01N33/15 , G01N33/48 , G01N33/53 , G01N33/531 , G01N33/566 , G01N33/577 , G01N33/58 , G01N33/68
CPC分类号： G01N33/5011 , C40B30/04 , G01N33/5008 , G01N33/5432 , G01N33/566 , G01N33/6845 , G01N33/6854 , G01N33/6863
摘要： PROBLEM TO BE SOLVED: To provide a method of identifying ligands that are internalized into a cell. SOLUTION: The metal chelate lipid composition contains a lipid, a hydrophilic polymer bound to the lipid, and a metal chelate group bound to the hydrophilic polymer. The metal chelate group can form a chelate bond with an epitope tag and the effector bound to the metal chelate lipid in the method for delivering the effector to a cell, including bringing the metal chelate lipid into contact with a ligand. The ligand can contain the epitope tag, and the cell specifically binds with the ligand, and can optionally internalize the ligand. COPYRIGHT: (C)2008,JPO&INPIT
摘要翻译：待解决的问题：提供一种鉴定内在细胞的配体的方法。解决方案：金属螯合脂质组合物含有脂质，与脂质结合的亲水性聚合物和与亲水性聚合物结合的金属螯合基团。金属螯合基团可以与表位标签形成螯合键，并且在用于将效应物递送至细胞的方法中与金属螯合物脂质结合的效应，包括使金属螯合脂质与配体接触。配体可以含有表位标签，并且细胞与配体特异性结合，并且可以任选地内化配体。版权所有（C）2008，JPO＆INPIT

4. 发明专利

JP2007006899A Self-assembling polynucleotide delivery system 有权
标题翻译：自组装多核苷酸递送系统
公开(公告)号：JP2007006899A
公开(公告)日：2007-01-18
申请号：JP2006262396
申请日：2006-09-27
申请人： Univ California , ザリージェンツオブザユニバーシティオブカリフォルニア
发明人： SZOKA FRANCIS C JR , HAENSLER JEAN
IPC分类号： C12N15/09 , A61K9/127 , A61K31/70 , A61K31/7125 , A61K38/00 , A61K47/48 , A61K48/00 , A61P11/00 , A61P13/00 , A61P19/00 , A61P43/00 , C07D401/14 , C07F9/10 , C07K7/66 , C07K14/025 , C08G83/00 , C12N15/87
CPC分类号： C07D401/14 , A61K9/1271 , A61K9/1272 , A61K47/54 , A61K47/543 , A61K47/55 , A61K47/645 , A61K47/6949 , A61K48/00 , B82Y5/00 , C07F9/10 , C08G83/003 , C08G2261/312 , C12N15/87
摘要： PROBLEM TO BE SOLVED: To provide a composition for bringing a polynucleotide into a subcellular component of eukaryotic cells and a method for introducing a polynucleotide into cells in vitro. SOLUTION: The composition includes polynucleotides, functional agents, DNA-binding components, cell recognition components, charge-neutralization and membrane-permeabilization components, and subcellular localization components. COPYRIGHT: (C)2007,JPO&INPIT
摘要翻译：待解决的问题：提供将多核苷酸引入真核细胞的亚细胞组分的组合物和将多核苷酸引入细胞体外的方法。组合物包括多核苷酸，功能试剂，DNA结合组分，细胞识别组分，电荷中和和膜透化组分以及亚细胞定位组分。版权所有（C）2007，JPO＆INPIT

5. 发明专利

JP2006312650A Orally administered peptide to ameliorate atherosclerosis 有权
标题翻译： ORALLY ADMINISTERED PEPTIDE TO AMELIORATE ATHEROSCLEROSIS
公开(公告)号：JP2006312650A
公开(公告)日：2006-11-16
申请号：JP2006220831
申请日：2006-08-14
申请人： Univ California , ザリージェンツオブザユニバーシティオブカリフォルニア
发明人： FOGELMAN ALAN M , ANANTHARAMAIAH GATTADAHALLI M , NAVAB MOHAMAD
IPC分类号： A61K38/00 , C07K7/08 , A61K38/43 , A61K38/44 , A61P7/00 , A61P9/00 , A61P9/10 , A61P11/00 , A61P17/00 , A61P17/02 , A61P19/02 , A61P19/10 , A61P25/28 , A61P29/00 , A61P31/04 , A61P31/06 , A61P31/08 , A61P31/10 , A61P31/12 , A61P31/18 , A61P33/00 , A61P37/02 , A61P37/06 , A61P39/06 , A61P43/00 , C07K14/00 , C07K14/775
CPC分类号： C07K14/775 , A61K38/00 , Y02P20/55
摘要： PROBLEM TO BE SOLVED: To provide a new peptide that ameliorates one or more symptoms of atherosclerosis. SOLUTION: The peptide comprises at least one class A amphiphilic helix and at least one D-amino acid. The peptide is highly stable and easily administered via an oral route. COPYRIGHT: (C)2007,JPO&INPIT
摘要翻译：要解决的问题：提供改善一种或多种动脉粥样硬化症状的新肽。解决方案：肽包含至少一个A类两亲螺旋和至少一个D-氨基酸。该肽是高度稳定的并且通过口服途径容易地施用。版权所有（C）2007，JPO＆INPIT

6. 发明专利

JP2006188528A Composition for prevention and treatment of hepatocellular cancer 审中-公开
标题翻译：用于预防和治疗肝细胞癌的组合物
公开(公告)号：JP2006188528A
公开(公告)日：2006-07-20
申请号：JP2006038626
申请日：2006-02-15
申请人： Univ California , ザリージェンツオブザユニバーシティオブカリフォルニア
发明人： ECONOMOU JAMES S , BUTTERFIELD LISA H , RIBAS BRUGUERA ANTONI
IPC分类号： A61K48/00 , C12N15/09 , A61K35/12 , A61K38/00 , A61K38/17 , A61P35/00 , A61P35/04 , A61P37/04 , A61P43/00 , C07K14/47
CPC分类号： C07K14/4715 , A61K38/1709
摘要： PROBLEM TO BE SOLVED: To provide a new composition for preventing or treating a cancer in a mammal by creating an immune response in the mammal. SOLUTION: The present invention provides a composition for preventing or treating a cancer in a mammal by creating an immune response in the mammal. The composition comprises an immune system cell transformed by a recombinant vector expressing α-fetoprotein cDNA composed of a nucleic acid sequence represented by sequence No. 1, wherein the immune response activates α-fetoprotein peptide-specific T lymphocytes and creates the immune response against cancer cell having surface markers thereof. COPYRIGHT: (C)2006,JPO&NCIPI
摘要翻译：待解决的问题：通过在哺乳动物中产生免疫应答来提供用于预防或治疗哺乳动物癌症的新组合物。解决方案：本发明提供了通过在哺乳动物中产生免疫应答来预防或治疗哺乳动物的癌症的组合物。该组合物包含由表达由序列号1表示的核酸序列构成的甲胎蛋白cDNA的重组载体转化的免疫系统细胞，其中所述免疫应答激活α-甲胎蛋白肽特异性T淋巴细胞并产生针对癌症的免疫应答电池具有表面标记。版权所有（C）2006，JPO＆NCIPI

7. 发明专利

JP2006045244A Method for increasing bioavailability of oral pharmaceutical compositions 审中-公开
标题翻译：增加口服药物组合物生物利用度的方法
公开(公告)号：JP2006045244A
公开(公告)日：2006-02-16
申请号：JP2005292093
申请日：2005-10-05
申请人： Univ California , ザリージェンツオブザユニバーシティオブカリフォルニア
发明人： BENET LESLIE , WU CHI YUAN
IPC分类号： A61K47/46 , A61K47/48 , A61K31/496 , A61K38/00 , A61K38/12 , A61K38/13 , A61K38/19 , A61K45/00 , A61K45/06 , A61P43/00 , C12Q1/26
CPC分类号： C12Q1/26 , A61K31/49 , A61K31/54 , A61K38/13 , A61K45/06 , G01N2500/04 , Y10S514/946 , A61K31/495 , A61K2300/00
摘要： PROBLEM TO BE SOLVED: To provide a method for increasing bioavailability of an orally administered hydrophobic pharmaceutical compound. SOLUTION: The method comprises administering the pharmaceutical compound to a mammal in need of treatment with the compound concurrently with a bioenhancer comprising an inhibitor of a cytochrome P450-3A enzyme or an inhibitor of P-glycoprotein-mediated membrane transport. The bioenhancer is present in sufficient amount to provide bioavailability of the compound in the presence of the bioenhancer greater than the bioavailability of the compound in the absence of the bioenhancer. COPYRIGHT: (C)2006,JPO&NCIPI
摘要翻译：待解决的问题：提供一种提高口服给药的疏水药物化合物的生物利用度的方法。解决方案：该方法包括向需要与化合物一起治疗的哺乳动物施用药物化合物与包含细胞色素P450-3A酶的抑制剂或P-糖蛋白介导的膜转运抑制剂的生物降解剂同时进行。存在足够量的生物增强剂以在生物催化剂存在下提供化合物的生物利用度，该生物利用度大于化合物在不存在生物催化剂时的生物利用度。版权所有（C）2006，JPO＆NCIPI

8. 发明专利

JP2005249784A Nonresonant micromachined gyroscope having mode decoupled structure 审中-公开
标题翻译：具有模式解构结构的非骨骼微血管造影
公开(公告)号：JP2005249784A
公开(公告)日：2005-09-15
申请号：JP2005053238
申请日：2005-02-28
申请人： Univ California , ザリージェンツオブザユニバーシティオブカリフォルニア
发明人： ACAR CENK , SHKEL ANDREI M
IPC分类号： G01P9/04 , G01C19/56
CPC分类号： G01C19/5719
摘要： PROBLEM TO BE SOLVED: To attain a large oscillation amplitude without resonance, in a four-degrees-of-freedom nonresonant micromachined gyroscope, using dynamical amplification both in a 2-degree-of-freedom drive-directional oscillator and a 2-degree-of-freedom sensing-directional oscillator having decoupled structure. SOLUTION: The overall 4--degree-of-freedom dynamical system is provided with three proof masses. The second and third masses form the 2-degree-of-freedom sensing-directional oscillator. The first mass and the combination of the second and third masses form the 2-degree-of-freedom drive-directional oscillator. Frequency responses of the drive mode oscillator and sensing-mode oscillator have two resonant peaks and a flat region between the peaks. A device thereof is nominally operated in the flat regions of response curves belonging to the drive mode oscillator and sensing-mode oscillator, and a gain in the region is less sensitive to frequency fluctuation. This is achieved by designing anti-resonance frequencies for drive and sensing to be matched. COPYRIGHT: (C)2005,JPO&NCIPI
摘要翻译：要解决的问题为了在没有共振的情况下获得大的振荡幅度，在四自由度非谐振微加工陀螺仪中，使用在2自由度驱动方向振荡器和2自由度驱动方向振荡器中的动态放大具有解耦结构的自由度感应定向振荡器。解决方案：整体4自由度动力系统提供三个质量体系。第二和第三质量形成2度自由度感应定向振荡器。第一质量和第二和第三质量的组合形成2自由度驱动方向振荡器。驱动模式振荡器和感测模式振荡器的频率响应具有两个谐振峰值和峰值之间的平坦区域。其装置名义上在属于驱动模式振荡器和感测模式振荡器的响应曲线的平坦区域中工作，并且该区域中的增益对频率波动较不敏感。这是通过设计用于驱动和感测匹配的反共振频率来实现的。版权所有（C）2005，JPO＆NCIPI

9. 发明专利

JP2005247864A 8-aza, 6-aza, and 6,8-diaza-1,4-dihydroquinoxaline-2,3-dione compounds 审中-公开
标题翻译： 8-AZA，6-AZA和6,8-二氮杂-1,4-二氢喹啉-2,3-二酮化合物
公开(公告)号：JP2005247864A
公开(公告)日：2005-09-15
申请号：JP2005121174
申请日：2005-04-19
申请人： Acea Pharmaceuticals Inc , Oregon State , Univ California , エイシア・ファーマシュウティカルズ,インコーポレイテッド , オレゴン州 , ザリージェンツオブザユニバーシティオブカリフォルニア
发明人： CAI SUI XIONG , WEBER ECKARD , KEANA JOHN F W
IPC分类号： C07D487/04 , A61K31/495 , A61K31/4985 , A61K31/519 , A61P9/10 , A61P21/00 , A61P21/02 , A61P25/00 , A61P25/02 , A61P25/04 , A61P25/08 , A61P25/14 , A61P25/20 , A61P25/22 , A61P25/28 , A61P25/36 , A61P43/00 , C07D471/04 , C07D475/00
CPC分类号： C07D471/04 , A61K31/495 , A61K31/4985 , C07D475/00
摘要： PROBLEM TO BE SOLVED: To provide a method for treating or preventing neuron loss, neurodegenerative diseases, and the injurious effects of excitatory amino acid overstimulation. SOLUTION: This medicinal composition contains a compound represented by formula [R 4 , R 5 and R 6 are each independently H, amino, a halogen atom or the like; R c and R d are each independently H, OH, amino or the like; (n) is 0 or 1] or its pharmaceutically acceptable salt. COPYRIGHT: (C)2005,JPO&NCIPI

10. 发明专利

JP2005247854A Use of fxr, ppar alpha and lxr alpha activators to restore barrier function, promote epidermal differentiation and inhibit proliferation 审中-公开
标题翻译：使用FXR，PPAR ALPHA和LXR ALPHA激活剂恢复障碍功能，促进皮下分化和抑制增殖
公开(公告)号：JP2005247854A
公开(公告)日：2005-09-15
申请号：JP2005062692
申请日：2005-03-07
申请人： United States Department Of Veterans Affairs , Univ California , アメリカ合衆国復員軍人援護省 , ザリージェンツオブザユニバーシティオブカリフォルニア
发明人： ELIAS PETER M , BASS NATHAN M , HANLEY KAREN , FEINGOLD KENNETH R
IPC分类号： A61K31/357 , A61K31/00 , A61K31/01 , A61K31/045 , A61K31/07 , A61K31/08 , A61K31/11 , A61K31/19 , A61K31/192 , A61K31/20 , A61K31/201 , A61K31/202 , A61K31/203 , A61K31/215 , A61K31/216 , A61K31/22 , A61K31/232 , A61K31/336 , A61K31/427 , A61K31/505 , A61K31/5575 , A61K31/56 , A61K31/575 , A61K31/592 , A61K45/00 , A61P17/00 , A61P17/02 , A61P17/06 , A61P17/08 , A61P17/16 , A61P35/00 , A61P43/00
CPC分类号： A61K31/20 , A61K31/00 , A61K31/045 , A61K31/08 , A61K31/11 , A61K31/192 , A61K31/201 , A61K31/202 , A61K31/215 , A61K31/216 , A61K31/22 , A61K31/336 , A61K31/505 , A61K31/56 , A61K31/575
摘要： PROBLEM TO BE SOLVED: To improve the disorders of the skin and mucous membranes that have a disrupted or dysfunctional epidermal barrier. SOLUTION: The disorders of the skin and mucous membranes that have the disrupted or dysfunctional epidermal barrier are treated or prevented by topical application of compounds that are either activators of farnesoid X receptor, activators of peroxisome proliferator-activated receptor α, and oxysterol activators of the LXRα receptor. The same compounds are also effective in treating disorders of epidermal differentiation and proliferation. COPYRIGHT: (C)2005,JPO&NCIPI

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式